

Supplementary materials for:

RNase Y-mediated regulation of the streptococcal pyrogenic exotoxin B

Laura Broglia^{1,2,3,4}, Solange Materne^{1,2}, Anne-Laure Lécivain^{1,2,5}, Karin Hahnke^{1,2}, Anaïs Le Rhun^{1,2,4,5*} and Emmanuelle Charpentier^{1,2,3,4,5*}

¹Max Planck Unit for the Science of Pathogens, D-10117 Berlin, Germany

²Max Planck Institute for Infection Biology, Department of Regulation in Infection Biology, D-10117 Berlin, Germany

³Institute for Biology, Humboldt University, D-10115 Berlin, Germany

⁴Helmholtz Centre for Infection Research, D-38124 Braunschweig, Germany

⁵The Laboratory for Molecular Infection Medicine Sweden (MIMS), Umeå Centre for Microbial Research (UCMR), Department of Molecular Biology, Umeå University, S-90187 Umeå, Sweden

*Co-corresponding authors

Correspondence:

Anaïs Le Rhun, Email: lerhun@mpiib-berlin.mpg.de

Emmanuelle Charpentier, Email: research-charpentier@mpiib-berlin.mpg.de

Supplementary materials include:

Supplementary Figures

Supplementary Table I

Supplementary Table II

Supplementary Figures




Figure S1. *ropB*-*speB* intergenic region

A-B. Total and 5' end coverages (black for positive strand, grey for negative strand) are indicated between brackets.

A. Zoom on *speB* promoters, P (top panel) and P1 (bottom panel). The predicted – 35 and – 10 motifs were mapped for P and P1. The putative RopB binding sites, consisting

of inverted repeats (dark blue boxes and arrows) located within direct repeats (light blue boxes), are annotated upstream of P and P1 [1,2]. **B.** Characterization of the *ropB*-*speB* intergenic region by RNA sequencing analysis. The *ropB* (P_{ropB}) and *speB* (P1) TSSs are shown with black bent arrows. P_{ropB} is located – 369 nt relative to the *ropB* start codon (not indicated here). In the experimental conditions used in this study, SPy_2041 is not transcribed.




Figure S2. Unknown RNase(s) process the *speB* mRNA 5' UTR

A. Schematic drawing of *speB* mRNA 5' UTR. Processing by RNase Y (orange scissors) and unknown RNase(s) (grey scissors) are indicated (left panel). The primer used (black arrow) for primer extension (right panel) and the expected cDNA sizes (green lines) are depicted. The processed 5' ends of *speB* mRNA 5' UTR were identified using primer extension analyses (right panel) in WT, *rny* (RNase Y) deletion mutant (Δrny), *rnc* (RNase III) deletion mutant (Δrnc), *mrnc* (Mini-III) deletion mutant ($\Delta mrnc$), *rhnb* (RNase HII) deletion mutant ($\Delta rhnb$), *pnpA* (PNPase) deletion mutant ($\Delta pnpA$), *yhaM* (YhaM) deletion mutant ($\Delta yhaM$) and *rnr* (RNase R) deletion mutant (Δrnr) at early-stationary growth phase. **B.** Zoom on the processing sites (grey triangles) of *speB* mRNA 5' UTR at positions - 77 nt and - 78 nt (relative to the *speB* start codon) retrieved by RNA sequencing analysis. The total and the 5' end coverages are indicated between brackets.




Figure S3. Secondary structure prediction of the *speB* mRNA 5' UTR

A. Schematic drawing of *speB* mRNA 5' UTR (containing SpeB Inducing Peptide (SIP), *orf2*, SPy_2040) and *speB* coding DNA sequence (CDS). The positions corresponding to the cleavage sites of RNase Y and of unidentified RNase(s) are represented with orange and grey triangles, respectively. The two Gs located upstream of the RNase Y processing sites at positions – 137 nt (G₁) and – 131 nt (G₂) are indicated. The minimal folding energy (MFE, ΔG in Kcal/mol) was calculated both 100 nt upstream and downstream of the RNase Y cleavage site (– 137 nt). The numbers indicate the

distance in nt to *speB* start codon. **B.** RNA folding of a portion of *speB* 5' UTR (from position – 153 nt to the *speB* start codon). The free energy of the thermodynamic ensemble is – 31.48 kcal/mol. The cleavages by RNase Y and unidentified RNase(s) are indicated by orange and grey scissors, respectively (right panel). The *speB* ribosome binding site (RBS) and start codon are represented in purple (left panel). The same structure was colored by base-pairing probabilities (right panel). The color of the unpaired regions indicates the probability of being unpaired.




Figure S4. Isoforms of *speB* mRNA

Expression profile of *speB* locus and surrounding genes resulting from RNA sequencing analysis. The 5' ends retrieved are depicted with black bars. The genes (arrows) with the putative promoters (P and P1) and terminators are indicated. Putative ORFs (SPy_2040 and *orf-2*) and the sequence encoding the SpeB Inducing Peptide (SIP) are annotated in the *speB* 5' UTR. *speB* is co-transcribed with the SPy_2038 and *prsA* genes [3]. The cleavages by RNase Y and by unknown RNase(s) are depicted with orange and grey triangles, respectively. The primers used in the Northern blot

analyses (Figure 4A and 4B) are indicated below the locus. The expected transcript isoforms detectable with the primers targeting the 5' UTR (T1, T2 and T3) (Figure 4A) and the CDS (T1, T2, T4, T5) (Figure 4B) are shown as black curved lines and the sizes in nt are indicated.




Figure S5. Study of *speB* promoter activity

A. Schematic representation of luciferase (*ffluc*) fusion plasmids used in Figure 4A and S4B. The *speB* promoters were cloned upstream of the *ffluc* gene (*PspeB-ffluc*). The – 10 and – 35 motifs of P and P1 are depicted with green boxes. The putative RopB binding sites are indicated in blue. A control vector with *ffluc* expression under the control of a constitutive promoters (P23) was included in the analysis (*P23-ffluc*). **B.** The *speB* promoter activity was examined by luminescence assay performed in the WT and *speB* deletion mutant ($\Delta speB$) containing the luciferase fusion plasmids (*P23-ffluc* and *PspeB-ffluc*) at mid-logarithmic (ML) and early-stationary (ES) growth phases. Values indicate luminescence intensity of the samples relative to the control plasmid (*P23-ffluc*), normalized to the $OD_{620\text{ nm}}$. Mean and standard deviations (error bars) were calculated from three independent experiments, each with technical triplicates.




Figure S6. *covR* mRNA stability is affected by RNase Y

Study of the *covR* transcript stability by rifampicin assay at mid-logarithmic phase of growth in WT and *rny* (RNase Y) deletion mutant (Δrny) (lower panel). The minutes after stopping transcription upon the addition of antibiotic are indicated. 16S rRNA was used as a loading control. The primer used is indicated by a black arrow.




Figure S7. An sRNA arises from *speB* mRNA 5' UTR processing

Expression profile of a small RNA (sRNA) previously identified in *speB* 5' UTR by sRNA sequencing (Spy_sRNA1699993) [4]. Total, 5' end and 3' end coverages are indicated between brackets. Orange and grey bars pinpoint the positions of RNase Y and unidentified RNase(s) cleavage sites annotated in this study, respectively. The green bar denotes the putative sRNA 3' end.

Supplementary Table I. Strains, plasmids and oligos used in this study.

Strain	Relevant characteristics	Source
<u>Streptococcus pyogenes</u>		
<u>WT</u>		
EC2224	SF370 (M1 serotype)	ATCC 700294
<u>Δrny</u>		
EC2246	EC2224Δrny::lox72	[5]
<u>Δrnc</u>		
EC2249	EC2224Δrnc::lox72	[5]
<u>Δrnr</u>		
EC2254	EC2224Δrnr::lox72	This study
<u>ΔpnpA</u>		
EC2297	EC2224ΔpnpA::lox72	This study
<u>Δrny::rny</u>		
EC2298	EC2246Δlox72::rny-TT3-lox72	This study
<u>ΔyhaM</u>		
EC2347	EC2224ΔSPy_0267::lox71- PermAM/B-ermAM/B-lox66	This study
<u>ΔrnhB</u>		
EC2251	EC2224ΔrnhB::lox72	This study
<u>Δmrnc</u>		
EC2271	EC2224Δmrnc::lox72	This study
<u>ΔspeB</u>		
EC2356	EC2224ΔspeB::lox72	This study
<u>Saccharomyces cerevisiae</u>		
S228C	BY4741 (Host for cloning)	Euroscarf, Frankfurt
<u>Escherichia coli</u>		
RDN204	Top10 (Host for cloning)	Invitrogen

Plasmid	Relevant characteristics	Source
<u>Plasmids used for gene deletion in <i>S. pyogenes</i></u>		
pEC454	pUC19Ωlox71-ermAM/B-lox66	Laboratory collection
pEC455	pEC85ΩPgyrA-cre	Laboratory collection
pEC707	pUC19, pMB1, ampR	New England Biolabs

pEC748	pUC19 Ω rhB::lox71-PermAM/B-ermAM/B-lox66	This study
pEC749	pUC19 Ω mrnc::lox71-PermAM/B-ermAM/B-lox66	This study
pEC801	pSEVA141, pRO1600/ColeI, <i>ampR</i>	de Lorenzo's lab
pEC2145	pEC801 Ω speB::lox71-PermAM/B-ermAM/B-lox66	This study
pEC545	pJET1.2 Ω mrnkoup-lox71-PermAM/B-ermAM/B-lox66-rnrkodw	This study
pEC750	pEC707 Ω pnpAkoup-lox71-PermAM/B-ermAM/B-lox66-pnpAkodw	This study
pEC822	pEC801 Ω SPy_0267koup-lox71-PermAM/B-ermAM/B-lox66-SPy_0267kodw	This study

Chromosomal complementation of *rny* in *S. pyogenes*

pEC802	pRS426 Ω rnyup-rny-TT3-lox71-PermAM/B-ermAM/B-lox66-rnydw	This study
--------	--	------------

speB ectopic expression in *S. pyogenes*

pEC85	<i>repDEG</i> -pAM β 1, <i>aphIII</i> -Pjh1, <i>ColeE</i> 1	Laboratory collection
pEC2146	pEC85 Ω PgyrAspeB	This study
pEC2249	pEC85 Ω PgyrA-speB(G-137A)	This study
pEC2250	pEC85 Ω PgyrA-speB(G-131A)	This study
pEC2263	pEC85 Ω PgyrA-speB(G-137A_G-131A)	This study
pEC2264	pEC85 Ω PgyrA-speB(Δ -147-121)	This study
pEC2265	pEC85 Ω PgyrA-speB(Δ -157-111)	This study

Luminescence assay in *S. pyogenes*

pEC2173	pLZ12Km2-P23R:TA: <i>ffluc</i>	Addgene plasmid # 88900
pEC2248	pEC2173 Ω PspeB	This study

Oligo	Sequence 5'-3' ^a	F/R ^b	Usage ^c	Target ^d
<u>ΔrnyΩrny</u>				
OLEC3584	GTAACGCCAGGGTTTTCCAGTCACGACGCTCTTCAAACGAAA AAGAGG	F	Cloning	Up fragment (pEC802)
OLEC3579	CGAGAAAAAAGGCCCACTTTTGTGGGCCTTTTTACGCAAGAA GCCACTACTTGGCATAATCAACCGCTCTCATCTC	R	Cloning	
OLEC3480	AAGTGGGCCTTTTTTCTCGGATTACCGTTCTATAGCATACATT ATACGAAGTTATCCG	F	Cloning	lox71- ermAM/B- lox66 (pEC454)
OLEC3572	TACCGTTCTGTATAATGTATGCTATACGAAGTTATTTATTTCTCC CGTTAAATAATAGATAAC	R	Cloning	
OLEC2000	ATAGCATACATTATACGAACGGTAAAAAAGAGGAATTATCTCT TTTTCTTTATGA	F	Cloning	Down fragment (pEC802)
OLEC3585	GCGGATAACAATTTACACAGGAAACAGCGTAAAATCACAAGT GAATACTTGG	R	Cloning	
OLEC2785	TCGCAATCGTTGAAAATCAT	F	PCR, SEQ	Upstream <i>rny</i>
OLEC2503	GACAGCTTCACGTTAGCTGAAG	R	PCR, SEQ	Downstream <i>rny</i>
<u>ΔrhB</u>				
OLEC3340	GGTGGTGGATCCCGAAGTGAAGCTAATCATGC	F	Cloning	Up fragment (pEC748)
OLEC2517	TATAATGTATGCTATACGAACGGTAATACTAGTCGGCATCCATA TCTCC	R	LM-PCR	
OLEC2518	ATAGCATACATTATACGAACGGTATAAAAAGTTCTGTTTTAGC AGAATTTTTTCTTTT	F	LM-PCR	Dw fragment (pEC748)
OLEC3341	GGTGGTGGATCCCTGGGACAGCAAAAATGTCTCG	R	Cloning	

Oligo	Sequence 5'-3' ^a	F/R ^b	Usage ^c	Target ^d
OLEC2520	TTGCAAGCAAAAACTGTAAAGACTTAAAAG	F	SEQ	Upstream <i>rnhB</i>
OLEC2521	CATAATATCCCATTTTTAAGAACTGTCAATA	R	SEQ	Downstream <i>rnhB</i>
<u>Δmrnc</u>				
OLEC2034	GATGATGGATCCCCCTGTCAGAACTTGAAGTTGGAG	F	Cloning	Up fragment (pEC749)
OLEC3353	ATAGCATACATTATACGAACGGTAAATTCACATCAACTGGATTAGTCAC	R	LM-PCR	
OLEC3352	TATAATGTATGCTATACGAACGGTACATAGGTCTGAAGTAAAGGTAGAGAG	F	LM-PCR	Dw fragment (pEC749)
OLEC2033	GGTGGTGAGCTCCAATAGTATCTTTATCTTCCATGAG	R	Cloning	
OLEC2005	CCTCGTGTTATGGATTATATAGCA	F	SEQ	Upstream <i>mrnc</i>
OLEC2006	AGGCGTCCATGAAATAGCGACCTT	R	SEQ	Downstream <i>mrnc</i>
<u>ΔspeB</u>				
OLEC7565	AAAGGATCCATGTCAAAAAATACGTTACGCATG	F	Cloning	Up fragment (pEC2145)
OLEC7566	TATAATGTATGCTATACGAACGGTATTTTTTATACCTCTTTCAAATAAGTTAATCTAC	R	LM-PCR	
OLEC7902	ATAGCATACATTATACGAACGGTAGACGGACGTAACCTCTACCATGTT	F	LM-PCR	Dw fragment (pEC2145)
OLEC7569	AAAGGATCCTGTTGTGTGATGATTGACAAGCTG	R	Cloning	
OLEC7563	TGAATGCCTAATGAATTCACGG	F	PCR, SEQ	Upstream <i>speB</i>
OLEC7570	GTGTTTTTGGTCTCATTGTAGAAGT	R	PCR, SEQ	Downstream <i>speB</i>
<u>Δrnr</u>				
OLEC2897	AAAGGATCCGGAGATCGATTTGGCAATCA	F	Cloning	Up fragment (pEC545)
OLEC2535	TATAATGTATGCTATACGAACGGTAACCTAATTTCTATTCTGTTTTGTTGTTGG	R	LM-PCR	
OLEC2536	ATAGCATACATTATACGAACGGTAAAAAAGAAGAGTCGTAAAAGGAGTTAACT	F	LM-PCR	Dw fragment (pEC545)
OLEC2898	AAAGGTACCATCTTTGGGGTCTCGCTTTT	R	Cloning	
OLEC2538	CTCACAACCTAATGTTTACTTCAGGC	F	PCR, SEQ	Upstream <i>rnr</i>
OLEC2539	TATTGGCATAGAGATAACCATCTACATA	R	PCR, SEQ	Downstream <i>rnr</i>
<u>ΔpnpA</u>				
OLEC3350	GCTAGGATCCCAGTTCTTATATTGGCTTTGCC	F	Cloning	Up fragment (pEC750)
OLEC2541	TATAATGTATGCTATACGAACGGTAATATTCTCCTTTTAATTTTCAGAGGGG	R	LM-PCR	
OLEC2542	ATAGCATACATTATACGAACGGTAGAAAAAAGAAGAATAACATGACTAAATCAAATGAA	F	LM-PCR	Dw fragment (pEC750)
OLEC3351	GCTAGGATCCCTTTGATGCCTGGATAAGTTAGG	R	Cloning	
OLEC2544	CTAAACGTTAAAGTCTTTTCAGACGGT	F	PCR, SEQ	Upstream <i>pnpA</i>
OLEC2545	ATGAAGACTCCAGGAGCGATTTG	R	PCR, SEQ	Downstream <i>pnpA</i>
<u>ΔyhaM (ΔSPy_0267)</u>				
OLEC3361	GAAGCTGCAGCCTCTTTTCGATTCTGTATCC	F	Cloning	Up fragment (pEC822)
OLEC2529	TATAATGTATGCTATACGAACGGTATTAATTTTCATTATTTCTCTTCTAATAAGGG	R	LM-PCR	
OLEC2530	ATAGCATACATTATACGAACGGTATGATCAGTGTTTCTCGAGTAATAGTTT	F	LM-PCR	Dw fragment (pEC822)
OLEC3362	GAAGGTCGACGCATTGGCAATAATACGACC	R	Cloning	
OLEC2532	GACCGGTCTGACAAACGCTTA	F	PCR, SEQ	Upstream SPy_0267
OLEC2533	GTCAATTTGCTCACGCTCTGATTG	R	PCR, SEQ	Downstream SPy_0267
<u>pEC2146</u>				
OLEC7968	CCTTTCTAGACTATCATTTTCAATGAAAGAAGTCACTAATAAAATGTGA	F	Cloning	PgylA (pEC455)
OLEC7969	CATAGTAGGCGCCTCCTTTTAACTTATTACATTGTACCATAATTAGGTAAAAATTGCGATGAT	R	LM-PCR	
OLEC7970	ATCATCGCAATTTTACCTAAATTATGGTACAATGTAATAAGGTTAAAGGAGGCGCCTACTATG	F	LM-PCR	<i>speB</i>
OLEC7971	CCCAGAATTCCTAAGGTTTGATGCCTACAACAGCAC	R	Cloning	

Oligo	Sequence 5'-3' ^a	F/R ^b	Usage ^c	Target ^d
pEC2249				
OLEC8388	GTCAACTAACCGTATTATTGTCTATTACCAT	F	TS-PCR	speB 5' UTR (pEC2146)
OLEC8389	GTCAACTAACCGTATTATTGTCTATTACCAT	R	TS-PCR	
pEC2250				
OLEC8390	GTCAACTAACCGTGTTATTATCTATTACCAT	F	TS-PCR	speB 5' UTR (pEC2146)
OLEC8391	ATGGTAATAGATAATAACACGGTTAGTTGAC	R	TS-PCR	
pEC2263				
OLEC8392	GTCAACTAACCGTATTATTATCTATTACCAT	F	TS-PCR	speB 5' UTR (pEC2146)
OLEC8393	ATGGTAATAGATAATAATACGGTTAGTTGAC	R	TS-PCR	
pEC2264				
OLEC8394	GTTGGGTTGTCAGTGTTCATCATGGTATCAGCGACAT	F	TS-PCR	speB 5' UTR (pEC2146)
OLEC8395	ATGTCGCTGATACCATGATGACACTGACAACCCAAC	R	TS-PCR	
pEC2265				
OLEC8396	GAATAATTGGGTTGGGTTAGCGACATCGTATGATAA	F	TS-PCR	speB 5' UTR (pEC2146)
OLEC8397	TTATCATACGATGTCGCTAACCCAACCCAATTATTC	R	TS-PCR	
pEC2248				
OLEC8386	CGAGCTCATGTCAAGCCTTCCTAGTTGATGTCA	F	Cloning	speB 5' UTR
OLEC8387	TACCCGCGGTGGCTATATCATAGCTGCTTATTTTGCT	R	Cloning	
Sequencing				
OliRN228	GGAACGAAAACCTCACGTTAA	F	SEQ	pEC85
OLEC787	TGTGGTTACGTGGTTTTTAAC	R	SEQ	
OLEC3224	TGTA AACGACGGCCAGT	F	SEQ	pEC707 pEC2173
OLEC3225	CAGGAAACAGCTATGACC	R	SEQ	
OLEC3600	CCAGGGTTTTCCAGTCACGAC	F	SEQ	pEC801
OLEC3590	AGCGGATAACAATTTACACAGGA	R	SEQ	
OLEC1938	TCAATCGAGAATATCGTCAACTGTTTACTAAA	F	SEQ	ermAM/B
OLEC1937	TTGCTGTTTCGATTTTATGATATGGTGC	R	SEQ	
OLEC5336	GGGGGATGTGCTGCAAGGCG	F	SEQ	pEC802
OLEC5337	TCCGGCTCCTATGTTGTGTGG	R	SEQ	
Primer extension analyses				
OLEC2406	ACTACCATTTTGCAAAGGAAC	R	PE	speB 5' UTR
OLEC3903	TAACGGTACATTGGACACACCTCC	R	PE	
OLEC3904	TATACCTCTTTCAAATAAGTTAATCTACTGC	R	PE	
OLEC3970	TGGGTTAGCAAGAACAATCC	R	PE	speB CDS
Northern blot analyses				
OLEC5802	AACCACATAGTAGGCGCCTC	R	NB	speB 5' UTR
OLEC7431	GCAACACATCCTGTAGCTGC	R	NB	speB CDS
OLEC1542	CATGACACGATTCATATTAGTC	R	NB	covR CDS
OliRN243	CGTTGTACCAACCATTTGTAGC	R	NB	16S rRNA

^a *italic*: sequence annealing to the template; underlined: restriction site.

^b F: forward primer; R: reverse primer.

^c LM-PCR: ligation-mediated PCR; TS-PCR: two-stage PCR; SEQ: sequencing; PE: primer extension; NB: Northern blot;

^d 5' UTR: 5' untranslated region; CDS: coding DNA sequence

Supplementary Table II. *speB* regulators potentially affected by RNase Y.

<i>speB</i> regulators	Function	References
Direct transcriptional regulators		
<i>ropB</i>	Activator	[1,6–8]
<i>covRS</i>	Repressor	[9–11]
<i>ccpA</i>	Activator	[11–13]

<i>speB</i> regulators	Function	References
Indirect transcriptional regulators via RopB		
LacD.1	Repressor	[14]
<i>vfr</i>	Repressor	[15,16]
SIP	Activator	[2,17]

Except for *vfr* abundance [18] and *ropB* stability [19], which were shown to be affected by RNase Y, the effect of RNase Y on the other regulators is to be confirmed [20]. SpeB Inducing Peptide (SIP) is encoded by the *speB* transcript, and therefore its expression is downregulated in the *my* deletion strain.

References

- [1] Neely MN, Lyon WR, Runft DL, et al. Role of RopB in growth phase expression of the SpeB cysteine protease of *Streptococcus pyogenes*. J Bacteriol. 2003;185:5166–5174.
- [2] Do H, Makthal N, VanderWal AR, et al. Leaderless secreted peptide signaling molecule alters global gene expression and increases virulence of a human bacterial pathogen. Proc Natl Acad Sci USA. 2017;114:E8498–E8507.
- [3] Ma Y, Bryant AE, Salmi DB, et al. Identification and characterization of bicistronic *speB* and *prsA* gene expression in the Group A Streptococcus. J Bacteriol. 2006;188:7626–7634.
- [4] Le Rhun A, Beer YY, Reimegård J, et al. RNA sequencing uncovers antisense RNAs and novel small RNAs in *Streptococcus pyogenes*. RNA Biol. 2016;13:177–195.
- [5] Le Rhun A, Lécrivain A-L, Reimegård J, et al. Identification of endoribonuclease specific cleavage positions reveals novel targets of RNase III in *Streptococcus pyogenes*. Nucleic Acids Res. 2017;45:2329–2340.
- [6] Lyon WR, Gibson CM, Caparon MG. A role for trigger factor and an Rgg-like regulator in the transcription, secretion and processing of the cysteine proteinase of *Streptococcus pyogenes*. EMBO J. 1998;17:6263–6275.
- [7] Chaussee MS, Ajdic D, Ferretti JJ. The *rgg* gene of *Streptococcus pyogenes* NZ131 positively influences extracellular SPE B production. Infect Immun. 1999;67:1715–1722.
- [8] Anbalagan S, McShan WM, Dunman PM, et al. Identification of Rgg binding sites in the *Streptococcus pyogenes* chromosome. J Bacteriol. 2011;193:4933–4942.
- [9] Heath A, DiRita VJ, Barg NL, et al. A two-component regulatory system, CsrR-CsrS, represses expression of three *Streptococcus pyogenes* virulence factors, hyaluronic acid capsule, streptolysin S, and pyrogenic exotoxin B. Infect Immun. 1999;67:5298–5305.
- [10] Miller AA, Engleberg NC, DiRita VJ. Repression of virulence genes by phosphorylation-dependent oligomerization of CsrR at target promoters in *S. pyogenes*. Mol Microbiol. 2001;40:976–990.
- [11] Graham MR, Smoot LM, Migliaccio CAL, et al. Virulence control in group A Streptococcus by a two-component gene regulatory system: global expression profiling and in vivo infection modeling. Proc Natl Acad Sci USA. 2002;99:13855–13860.
- [12] Kietzman CC, Caparon MG. CcpA and LacD.1 affect temporal regulation of *Streptococcus pyogenes* virulence genes. Infect Immun. 2010;78:241–252.

- [13] Shelburne SA, Keith D, Horstmann N, et al. A direct link between carbohydrate utilization and virulence in the major human pathogen group A *Streptococcus*. *Proc Natl Acad Sci USA*. 2008;105:1698–1703.
- [14] Loughman JA, Caparon MG. A novel adaptation of aldolase regulates virulence in *Streptococcus pyogenes*. *EMBO J*. 2006;25:5414–5422.
- [15] Ma Y, Bryant AE, Salmi DB, et al. *vfr*, a novel locus affecting cysteine protease production in *Streptococcus pyogenes*. *J Bacteriol*. 2009;191:3189–3194.
- [16] Shelburne SA, Olsen RJ, Makthal N, et al. An N-Terminal signal peptide of Vfr protein negatively influences RopB-dependent SpeB expression and attenuates virulence in *Streptococcus pyogenes*. *Mol Microbiol*. 2011;82:1481–1495.
- [17] Makthal N, Gavagan M, Do H, et al. Structural and functional analysis of RopB: a major virulence regulator in *Streptococcus pyogenes*. *Mol Microbiol*. 2016;99:1119–1133.
- [18] Kang SO, Caparon MG, Cho KH. Virulence gene regulation by CvfA, a putative RNase: the CvfA-Enolase complex in *Streptococcus pyogenes* links nutritional stress, growth-phase control, and virulence gene expression. *Infect Immun*. 2010;78:2754–2767.
- [19] Chen Z, Mashburn-Warren L, Merritt J, et al. Interference of a *speB* 5' untranslated region partial deletion with mRNA degradation in *Streptococcus pyogenes*. *Mol Oral Microbiol*. 2017;32:390–403.
- [20] Chen Z, Itzek A, Malke H, et al. Multiple roles of RNase Y in *Streptococcus pyogenes* mRNA processing and degradation. *J Bacteriol*. 2013;195:2585–2594.